United Kingdom· GB-APID-42588311000001100
Ebglyss 250mg/2ml solution for injection pre-filled syringes
A lebrikizumab product containing lebrikizumab, registered in United Kingdom by Almirall Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lebrikizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH10 (lebrikizumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Lebrikizumab · ATC D11AH10
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lebrikizumab costs, country by country.
Normalised to the WHO defined daily dose (8.9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lebrikizumab · price per daily dose (8.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.32
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lebrikizumab
- Manufacturer
- Almirall Ltd
- Country
- United Kingdom (GB)
- ATC code
- D11AH10
- ATC class
- Lebrikizumab
- Defined daily dose
- 8.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin8430308134145
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lebrikizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEBGLYSSAlmirall, S.A., Barcelona
- SwitzerlandEbglyss
- United StatesEBGLYSSEli Lilly and Company
- NorwayEbglyssAlmirall
- FranceEBGLYSS 250 mg, solution injectable en seringue préremplieALMIRALL (ESPAGNE)
- BelgiumEbglyss 250 mgAlmirall
- IcelandEbglyssAlmirall S.A.*
- Japanレブリキズマブ（遺伝子組換え）日本イーライリリー
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ebglyss
- Liechtenstein · Ebglyss
- Norway · Ebglyss
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc4e4b1c-a6b7-411f-b8f3-8dd5cc1e836d GET /v1/drugs/bc4e4b1c-a6b7-411f-b8f3-8dd5cc1e836d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42588311000001100",
"desc": "Ebglyss 250mg/2ml solution for injection pre-filled syringes (Almirall Ltd)",
"form": "Solution for injection",
"vpid": "42594011000001106",
"source": "dmd",
"vtm_id": "42592611000001107",
"strength": "125 mg",
"substance": "Lebrikizumab",
"ingredient": "Lebrikizumab",
"supplier_code": "13610411000001109"
}See everything about lebrikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.